Effect of ziprasidone hydrochloride and haloperidol on cognitive flexibility in schizophrenia

Abstract

Abstract: AIM: To explore the long-time efficacy of ziprasidone hydrochloride in the treatment of cognitive flexibility in schizophrenia.METHODS: 50 cases of patients continuously treated with ziprasidone hydrochloride and 50 cases of patients treated with haloperidol were included in the 12 months follow-up study. Cognitive flexibility was tested with Wisconsin card sorting test (WCST) and Trail Making Test.RESULTS: At the time of 12 months, all the scores of total trial, sorts, perseverative errors and random errors on WCST and all target of Trail Making Test were significantly decreased in the two groups of patients (P < 0.05 or P <0.01);but the decreased rate of perseverative errors on WCST of ziprasidone hydrochloride group were significantly higher than that of Haloperidol group(P <0.01).CONCLUSION: Compare with Haloperidol, ziprasidone hydrochloride has a better efficacy in the long-time treatment of cognitive flexibility in schizophrenia.

Key words: ziprasidone hydrochloride, haloperidol, schizophrenia, cognitive flexibility

CLC Number:

R964

JI Wei-dong, YANG Dao-liang, GUO Tian-you, YANG Chuang, ZHOU Jia-xiu, YAO Jing, HUANG Xiao-qi. Effect of ziprasidone hydrochloride and haloperidol on cognitive flexibility in schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1410-1413.

References

[1] Harvey PD, Meltzer H, Simpson GM, et al.Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia[J].Schizophr Res, 2004, 66(2 3):101-113.
[2] Paulsen JS, Salmon DP, Monsch AU, et al.Discrimination of cortical from subcortical dementias on the basis of memory and problem-solving[J].J Clin Psychol, 1995, 51(1):48-51.
[3] Lu L, Bigler ED.Performance on original and a Chineseversion of Trail Making Test Part B:A normative bilingual sample[J].J Appl Neuropsy-chology, 2000, 7(1):243-246.
[4] Smith EE, Jonides J.Storage and executive processes in the frontal lobes[J].Science, 1999, 283(11):1657-1661.
[5] Neuhaus AH, Opgen-Rhein C, Urbanek C, et al.COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia[J].Pharmacopsychiatry, 2009, 42(4):141-144.
[6] Gibel A, Ritsner MS.Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care:a 12-month, open-label, flexibledose, naturalistic observational trial[J].Clin Neuropharmacol, 2008, 31(4):204-220.
[7] Daban C, Amado I, BourdelMC, et al.Cognitive dysfunctions in medicated and unmedicated patients with recentonset schizophrenia[J].J Psychiatr Res, 2005, 39(2): 391-398.
[8] Woodward ND, Purdon SE, Meltzer HY, et al.A metaanalysis of neuropsychological change to clozapine, quetiapine and risperidone in schizophrenia[J].Int J Neuropsychopharmacol, 2005, 8(4):457-472.
[9] Tonmoy S.Cognitive effects of conventional and atypicalantipsychotics in schizophrenia[J].Br J Psychiatry, 1999, 174(Suppl 38):44-51.
[10] Weiser M, Shneider Beer M.Improment in cognition associated with novel antipsychotic drugs:a direct drug effect or reduction of EPS[J].Schizophr Res, 2000, 46(1):81-89.
[11] 朱培俊, 陈志恩, 张静, 等.阿立哌唑治疗精神分裂症的临床评价[J].中国临床药理学与治疗学, 2005, 10(10):978-980.
[12] Stip E, Chouinard S, Boulay LJ.On the trail of a cognitive enhancer for the treatment of schizophrenia[J].Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(3):219-232.
[13] 宋明柯, 胡国渊, 陈红专.M 胆碱受体调控的M 通道 — 神经精神药物的新靶点[J].中国临床药理学与治疗学, 2006, 11(11):1219-1224

[1]	LI Na, HAN Hongcan, WANG Jun. General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425.
[2]	YAN Pan, SHI Jianfei, LI Jing, WANG Shengdong, WANG Shuqi, WANG Chengpeng, SONG Mingfen. Effects of DRD2 and 5-HTR2A gene polymorphisms and their interaction on olanzapine in the treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1131-1138.
[3]	WAN Ping, LIU Liang, ZHANG Ping, ZHANG Zhongdong. Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1024-1029.
[4]	FAN Yao, XUE Yong, WANG Xin, CHEN Xuefei, ZHANG Xu, YAO Yingshui, SHEN Chong. Association analysis of apolipoprotein E polymorphisms and weight loss among schizophrenia patients with risperidone treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 288-295.
[5]	CAO Ting, LI Nana, CAI Hualin. Progress in neurosteroids related to the pathogenesis and treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 709-714.
[6]	CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua. Effect of paliperidone and olanzapine on patients with first-episode schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 466-470.
[7]	ZHOU Yong, Chen Xuefang, HUANG Hanjin. Efficacy and safety of amisulpride for schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1152-1157.
[8]	HANG Rong-hua, LI Ye-ping, WU Ming-fei, LI Rui. Relationship on medication compliance, antipsychotic side-effects and social support in schizophrenia outpatients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 912-915.
[9]	NI Ping, LV Hai-long, GUO Xiao-feng, ZHANG Li-li, XU Lin-yong. Comparison of curative effect and clinical influence factors of risperidone and olanzapine in the treatment of acute phrase of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 182-185.
[10]	TANG Ya-mei, ZHANG Xiang-hui, LIU Yong. Concentration change of NE, 5-HT and their metabolites in brain tissue in schizophrenia developmental models rat repeatedly treated with MK-801 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 721-726.
[11]	HANG Rong-hua, CHENG Wan-liang, WANG Rui-quan, WU Ming-fei. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 812-815.
[12]	LIU Lin-jing, XIU Mei-hong, ZHANG Xiang-yang, CHEN Da-chun. Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 313-317.
[13]	XU Ben-jian, CHEN Ju-feng. Efficacy and safety of paliperidone extended-release tablets as substituting medication in acute patients with schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 215-219.
[14]	HUANG Zhan-qin, JIANG Hong-yan, LI Jin-yu, LIU Xing-pin, ZHENG Yan-shan, GAO Fen-fei, CHEN Yi-cun, SHI Gang-gang. Effects of N-n-butyl haloperidol iodide on the proliferation of intima and vascular muscle cells of rabbit carotid artery after balloon injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1112-1117.
[15]	WU Xiao-li, WANG Ji-hui, ZHONG Zhi-yong, HAN Zi-li. Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1016-1020.